These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 15113026

  • 1. Acyclonucleoside iron chelators of 1-(2-hydroxyethoxy)methyl-2-alkyl-3-hydroxy-4-pyridinones: potential oral iron chelation therapeutics.
    Liu G, Men P, Kenner GH, Miller SC, Bruenger FW.
    Nucleosides Nucleotides Nucleic Acids; 2004; 23(3):599-611. PubMed ID: 15113026
    [Abstract] [Full Text] [Related]

  • 2. Molecular structure and biological and pharmacological properties of 3-hydroxy-2-methyl-1-(beta-D-ribofuranosyl or pyranosyl)-4-pyridinone: potential iron overload drugs for oral administration.
    Liu G, Bruenger FW, Miller SC, Arif AM.
    Bioorg Med Chem Lett; 1998 Nov 03; 8(21):3077-80. PubMed ID: 9873679
    [Abstract] [Full Text] [Related]

  • 3. A new approach for potential combined chelation therapy using mono- and bis-hydroxypyridinones.
    Santos MA, Gama S, Gil M, Gano L.
    Hemoglobin; 2008 Nov 03; 32(1-2):147-56. PubMed ID: 18274992
    [Abstract] [Full Text] [Related]

  • 4. Coordination chemistry and biology of chelators for the treatment of iron overload disorders.
    Bernhardt PV.
    Dalton Trans; 2007 Aug 14; (30):3214-20. PubMed ID: 17893764
    [Abstract] [Full Text] [Related]

  • 5. Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
    Rai BL, Dekhordi LS, Khodr H, Jin Y, Liu Z, Hider RC.
    J Med Chem; 1998 Aug 27; 41(18):3347-59. PubMed ID: 9719587
    [Abstract] [Full Text] [Related]

  • 6. PCTH: a novel orally active chelator for the treatment of iron overload disease.
    Lovejoy DB, Kalinowski D, Bernhardt PV, Richardson DR.
    Hemoglobin; 2006 Aug 27; 30(1):93-104. PubMed ID: 16540421
    [Abstract] [Full Text] [Related]

  • 7. Chemical features of in use and in progress chelators for iron overload.
    Nurchi VM, Crisponi G, Lachowicz JI, Medici S, Peana M, Zoroddu MA.
    J Trace Elem Med Biol; 2016 Dec 27; 38():10-18. PubMed ID: 27365273
    [Abstract] [Full Text] [Related]

  • 8. Oral iron chelators.
    Kwiatkowski JL.
    Hematol Oncol Clin North Am; 2010 Feb 27; 24(1):229-48. PubMed ID: 20113905
    [Abstract] [Full Text] [Related]

  • 9. Design of iron chelators with therapeutic application.
    Zhou T, Ma Y, Kong X, Hider RC.
    Dalton Trans; 2012 Jun 07; 41(21):6371-89. PubMed ID: 22391807
    [Abstract] [Full Text] [Related]

  • 10. Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
    Liu J, Obando D, Schipanski LG, Groebler LK, Witting PK, Kalinowski DS, Richardson DR, Codd R.
    J Med Chem; 2010 Feb 11; 53(3):1370-82. PubMed ID: 20041672
    [Abstract] [Full Text] [Related]

  • 11. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
    Chaston TB, Richardson DR.
    Am J Hematol; 2003 Jul 11; 73(3):200-10. PubMed ID: 12827659
    [Abstract] [Full Text] [Related]

  • 12. Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy.
    Kalinowski DS, Richardson DR.
    Chem Res Toxicol; 2007 May 11; 20(5):715-20. PubMed ID: 17402750
    [Abstract] [Full Text] [Related]

  • 13. Iron(III) chelating resins II. 3-Hydroxy-4(1H)-pyridinones-sepharose gels.
    Feng M, van der Does L, Bantjes A.
    J Biomater Sci Polym Ed; 1992 May 11; 4(2):145-54. PubMed ID: 1486065
    [Abstract] [Full Text] [Related]

  • 14. Removal of Fe3+ and Zn2+ from plasma metalloproteins by iron chelating therapeutics depicted with SEC-ICP-AES.
    Sooriyaarachchi M, Gailer J.
    Dalton Trans; 2010 Aug 28; 39(32):7466-73. PubMed ID: 20623073
    [Abstract] [Full Text] [Related]

  • 15. Drug evaluation: Deferitrin for iron overload disorders.
    Barton JC.
    IDrugs; 2007 Jul 28; 10(7):480-90. PubMed ID: 17642018
    [Abstract] [Full Text] [Related]

  • 16. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
    Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A.
    Curr Med Chem; 2004 Aug 28; 11(16):2161-83. PubMed ID: 15279556
    [Abstract] [Full Text] [Related]

  • 17. The evolution of iron chelators for the treatment of iron overload disease and cancer.
    Kalinowski DS, Richardson DR.
    Pharmacol Rev; 2005 Dec 28; 57(4):547-83. PubMed ID: 16382108
    [Abstract] [Full Text] [Related]

  • 18. Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity.
    Bernhardt PV, Chin P, Sharpe PC, Richardson DR.
    Dalton Trans; 2007 Aug 14; (30):3232-44. PubMed ID: 17893768
    [Abstract] [Full Text] [Related]

  • 19. Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overload.
    Hider RC, Liu ZD.
    Curr Med Chem; 2003 Jun 14; 10(12):1051-64. PubMed ID: 12678676
    [Abstract] [Full Text] [Related]

  • 20. The kinetics of dimethylhydroxypyridinone interactions with iron(iii) and the catalysis of iron(iii) ligand exchange reactions: implications for bacterial iron transport and combination chelation therapies.
    Harrington JM, Mysore MM, Crumbliss AL.
    Dalton Trans; 2018 May 22; 47(20):6954-6964. PubMed ID: 29721567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.